{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:39:16Z","timestamp":1763105956728,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40121-023-00823-z","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T07:01:31Z","timestamp":1686985291000},"page":"1849-1860","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Effectiveness of 8-Week Glecaprevir\/Pibrentasvir in Treatment-Na\u00efve, Compensated Cirrhotic HCV Patients"],"prefix":"10.1007","volume":"12","author":[{"given":"Nancy","family":"Reau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiujun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"823_CR1","unstructured":"WHO. Hepatitis C fact sheet https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c#:~:text=Hepatitis%20C%20is%20a%20liver,major%20cause%20of%20liver%20cancer2020 ["},{"key":"823_CR2","doi-asserted-by":"crossref","unstructured":"Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013\u20132016. Hepatology. 2019;69(3):1020\u201331.","DOI":"10.1002\/hep.30297"},{"key":"823_CR3","doi-asserted-by":"crossref","unstructured":"Ryerson AB, Schillie S, Barker LK, Kupronis BA, Wester C. Vital signs: newly reported acute and chronic hepatitis C cases\u2014United States, 2009\u20132018. Morb Mortal Wkly Rep. 2020;69(14):399.","DOI":"10.15585\/mmwr.mm6914a2"},{"issue":"14","key":"823_CR4","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.4254\/wjh.v7.i14.1843","volume":"7","author":"V Khullar","year":"2015","unstructured":"Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol. 2015;7(14):1843.","journal-title":"World J Hepatol"},{"issue":"2","key":"823_CR5","first-page":"172","volume":"7","author":"L Kuna","year":"2019","unstructured":"Kuna L, Jakab J, Smolic R, Wu GY, Smolic M. HCV extrahepatic manifestations. J Clin Transl Hepatol. 2019;7(2):172.","journal-title":"J Clin Transl Hepatol"},{"issue":"3","key":"823_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/cid\/civ860","volume":"62","author":"F Xu","year":"2016","unstructured":"Xu F, Moorman AC, Tong X, Gordon SC, Rupp LB, Lu M, et al. All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus. Clin Infect Dis. 2016;62(3):289\u201397.","journal-title":"Clin Infect Dis"},{"key":"823_CR7","doi-asserted-by":"crossref","unstructured":"Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy. Side effects and complications. Visc Med. 2019;35(3):161\u201370.","DOI":"10.1159\/000500963"},{"key":"823_CR8","unstructured":"European Association for the Study of the Liver. Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73(5):1170\u2013218."},{"key":"823_CR9","unstructured":"IDSA-AASLD. HCV guidance: recommendations for testing, managing, and treating hepatitis C. Arlington\/Alexandria: Infectious Disease Society of America\/American Association for the Study of Liver Diseases; 2020."},{"key":"823_CR10","doi-asserted-by":"crossref","unstructured":"Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1\u20136 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2020;72(3):441\u20139.","DOI":"10.1016\/j.jhep.2019.10.020"},{"issue":"5","key":"823_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/hep4.1049","volume":"1","author":"N Reau","year":"2017","unstructured":"Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS. Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy. Hepatol Commun. 2017;1(5):439\u201352.","journal-title":"Hepatol Commun"},{"key":"823_CR12","unstructured":"Flamm SL, Kort J, Marx S, Strezewski J, Bacon B, Curry MP, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir (G\/P) for treatment na\u00efve, non-cirrhotic patients with HCV infection in the TRIO health network. Anxiety. 2018;98(560):18."},{"key":"823_CR13","unstructured":"AbbVie Ltd. Mavyret (full prescribing information). 2020. https:\/\/www.rxabbvie.com\/pdf\/mavyret_pi.pdf. Accessed on 6 April 2021."},{"key":"823_CR14","unstructured":"AbbVie Ltd. AbbVie receives FDA approval of Mavyret\u00ae (glecaprevir\/pibrentasvir) to shorten treatment duration to eight weeks for treatment-na\u00efve patients with chronic hepatitis C and compensated cirrhosis across all genotypes. 2019. https:\/\/news.Abbvie.Com\/news\/press-releases\/abbvie-receives-fda-approval-mavyret-glecaprevirpibrentasvir-to-shorten-treatment-duration-to-eight-weeks-for-treatment-nave-patients-with-chronic-hepatitis-c-and-compensated-cirrhosis-across-all-genotypes.Htm. Accessed on 28 June 2021."},{"key":"823_CR15","unstructured":"AbbVie Ltd. Maviret: product information. 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf. Accessed on 17 March 2021."},{"key":"823_CR16","unstructured":"AbbVie Ltd. European Commission grants AbbVie marketing authorization shortening Maviret\u00ae (glecaprevir\/pibrentasvir) treatment duration to eight weeks for treatment-na\u00efve chronic HCV patients with genotype 3 and compensated cirrhosis. 2020. https:\/\/news.Abbvie.Com\/news\/press-releases\/european-commission-grants-abbvie-marketing-authorization-shortening-maviret-glecaprevirpibrentasvir-treatment-duration-to-eight-weeks-for-treatment-nave-chronic-hcv-patients-with-genotype-3-and-compensated-cirrhosis.Htm. Accessed on 28 June 2021."},{"issue":"3","key":"823_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","volume":"70","author":"R D'Ambrosio","year":"2019","unstructured":"D\u2019Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70(3):379\u201387.","journal-title":"J Hepatol"},{"issue":"2","key":"823_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2018","unstructured":"Wyles D, Poordad F, Wang S, Alric L, Felizarta F, Kwo PY, et al. Glecaprevir\/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and\/or prior treatment experience: A partially randomized phase 3 clinical trial. Hepatology. 2018;67(2):514\u201323.","journal-title":"Hepatology"},{"key":"823_CR19","doi-asserted-by":"crossref","unstructured":"Flamm S, Mutimer D, Asatryan A, Wang S, Rockstroh J, Horsmans Y, et al. Glecaprevir\/pibrentasvir in patients with chronic HCV genotype 3 infection: an integrated phase 2\/3 analysis. J Viral Hepat. 2019;26(3):337\u201349.","DOI":"10.1111\/jvh.13038"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.drugalcdep.2018.11.007","volume":"194","author":"GR Foster","year":"2019","unstructured":"Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, et al. Glecaprevir\/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug Alcohol Depend. 2019;194:487\u201394.","journal-title":"Drug Alcohol Depend"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.drugalcdep.2018.06.013","volume":"190","author":"MR Skeer","year":"2018","unstructured":"Skeer MR, Ladin K, Wilkins LE, Landy DM, Stopka TJ. \u2018Hep C\u2019s like the common cold\u2019: understanding barriers along the HCV care continuum among young people who inject drugs. Drug Alcohol Depend. 2018;190:246\u201354.","journal-title":"Drug Alcohol Depend"},{"key":"823_CR22","unstructured":"Jacobson IM, Welzel T, Dylla D, Luetkemeyer A, Feld JJ, Moreno C, et al., editors. Impact of prescribed treatment duration on hepatitis C treatment adherence: comparison of 8- and 12-week treatment with glecaprevir\/pibrentasvir. In: Hepatology. Hoboken: Wiley; 2019."},{"key":"823_CR23","doi-asserted-by":"crossref","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, de Ledinghen V, Muir AJ, Gschwantler M, et al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-naive patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2544\u201353 e6.","DOI":"10.1016\/j.cgh.2020.06.044"},{"key":"823_CR24","doi-asserted-by":"crossref","unstructured":"Lampertico P, Mauss S, Persico M, Barclay ST, Marx S, Lohmann K, et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-naive patients with compensated cirrhosis. Adv Ther. 2020;37(9):4033\u201342.","DOI":"10.1007\/s12325-020-01449-0"},{"key":"823_CR25","doi-asserted-by":"crossref","unstructured":"Persico M, Aglitti A, Milella M, Coppola C, Messina V, Claar E, et al. Real-life glecaprevir\/pibrentasvir in a large cohort of patients with hepatitis C virus infection: the MISTRAL study. Liver Int. 2019;39(10):1852\u20139.","DOI":"10.1111\/liv.14170"},{"key":"823_CR26","doi-asserted-by":"crossref","unstructured":"Flamm SL, Kort J, Marx SE, Strezewski J, Dylla DE, Bacon B, et al. Effectiveness of 8-week glecaprevir\/pibrentasvir for treatment-naive, compensated cirrhotic patients with chronic hepatitis C infection. Adv Ther. 2020;37(5):2267\u201374.","DOI":"10.1007\/s12325-020-01301-5"},{"key":"823_CR27","unstructured":"Zamor P, Dillon J, Dylla D, Mutimer DJ, Ghalib R, Colombo M, et al. Outcomes of patients interrupting glecaprevir\/pibrentasvir treatment: a case series from clinical trials. Hepatology. 2019;70:935A-A936."},{"key":"823_CR28","doi-asserted-by":"crossref","unstructured":"Lampertico P, Carri\u00f3n JA, Curry M, Turnes J, Cornberg M, Negro F, et al. Real-world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. J Hepatol. 2020;72(6):1112\u201321.","DOI":"10.1016\/j.jhep.2020.01.025"},{"issue":"20","key":"823_CR29","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878\u201387.","journal-title":"N Engl J Med"},{"issue":"21","key":"823_CR30","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993\u20132001.","journal-title":"N Engl J Med"},{"issue":"1","key":"823_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-016-3671-z","volume":"16","author":"ZC Rich","year":"2016","unstructured":"Rich ZC, Chu C, Mao J, Zhou K, Cai W, Ma Q, et al. Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals. BMC Public Health. 2016;16(1):1\u201310.","journal-title":"BMC Public Health"},{"key":"823_CR32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugpo.2018.06.019","volume":"59","author":"S Nouch","year":"2018","unstructured":"Nouch S, Gallagher L, Erickson M, Elbaharia R, Zhang W, Wang L, et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. Int J Drug Policy. 2018;59:76\u201384.","journal-title":"Int J Drug Policy"},{"key":"823_CR33","doi-asserted-by":"crossref","unstructured":"Gane EJ, De Ledinghen V, Dylla DE, Rizzardini G, Shiffman ML, Barclay ST, et al., editors. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials. In: The Liver Meeting Digital Experience\u2122; 2020 Nov 13\u201316: virtual.","DOI":"10.1111\/jvh.13600"},{"issue":"11","key":"823_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S2468-1253(17)30053-5","volume":"2","author":"B Emmanuel","year":"2017","unstructured":"Emmanuel B, Wilson EM, O\u2019Brien TR, Kottilil S, Lau G. Shortening the duration of therapy for chronic hepatitis C infection. Lancet Gastroenterol Hepatol. 2017;2(11):832\u20136.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"823_CR35","unstructured":"AbbVie Inc. MappingHepC. Available at: https:\/\/mappinghepc.com\/. Accessed on 3 Oct 2022."},{"key":"823_CR36","doi-asserted-by":"crossref","unstructured":"Reau N, Sulkowski MS, Thomas E, Sundaram V, Xu Q, Cheng WH, et al. Epidemiology and clinical characteristics of individuals with hepatitis C virus infection in the United States, 2017\u20132019. Adv Ther. 2021;38(12):5777\u201390.","DOI":"10.1007\/s12325-021-01928-y"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00823-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00823-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00823-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T18:19:31Z","timestamp":1690827571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00823-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00823-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2023,6,17]]},"assertion":[{"value":"20 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}